Surmodics Launches Pounce™ XL Thrombectomy System for Rapid Clot Removal
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical devices and in vitro diagnostic technologies, has officially announced the commercial release of its Pounce™ XL Thrombectomy System. This new system is the latest addition to the Pounce Thrombectomy Platform, which is designed to provide rapid, non-surgical removal of acute or chronic blood clots from peripheral arteries. The Pounce XL system is specifically intended for use in peripheral arteries ranging from 5.5–10 mm in diameter, sizes commonly found in iliac and femoral arteries.
The Pounce XL Thrombectomy System complements existing products in the Pounce Thrombectomy family, including the Pounce and Pounce LP (Low-Profile) systems. The Pounce system is designed for arteries between 3.5–6 mm in diameter, while the Pounce LP is intended for smaller arteries ranging from 2–4 mm. Together, these systems cover a wide range of vessel diameters from 2–10 mm, offering a comprehensive solution for the removal of peripheral arterial thrombi and emboli throughout the lower and upper extremities.
A major advantage of the Pounce Thrombectomy Platform is its simplicity and ease of use. The system is fully mechanical, utilizing proprietary dual-basket technology to remove blood clots without the need for capital equipment. This platform is associated with a low risk of distal embolization, does not require thrombolytics (which helps streamline treatment), and avoids aspiration, reducing the risk of blood loss. Moreover, the system is atraumatic to vessel walls, reducing the likelihood of flow-limiting dissection.
The Pounce XL system has already been in limited market release (LMR) since January 2025. Dr. Anna Marjan, a vascular surgeon at Allina Health Mercy Hospital in Coon Rapids, Minnesota, was among the physicians who used the system during its LMR phase. According to Dr. Marjan, “Removing organized clot from large peripheral arteries without a surgical cutdown can be very challenging.
In our first use of the Pounce XL Thrombectomy System, we were able to extract a large amount of acute and subacute clot from the infrarenal aorta and common iliac arteries in a severely ischemic patient with just three passes of the device.” She further emphasized that avoiding surgical cutdown not only eliminates the need for general anesthesia but also reduces the risk of surgical-site infection, thus offering significant benefits to patients.
The effectiveness of the Pounce Thrombectomy Systems, including the Pounce XL, is backed by real-world data from the PROWL registry, a retrospective multicenter study in the U.S. The registry analyzes the use of the Pounce platform for removing thrombi and emboli in peripheral arteries. In an interim analysis of 74 patients with limb ischemia caused by acute, subacute, or chronic infrainguinal vessel occlusions, the average time for using the Pounce Thrombectomy Platform was just 20.3 minutes. Additionally, 79.7% of patients did not require any additional clot removal treatment after using the Pounce system. The study reported minimal device-related adverse events, with only one case of flow-limiting dissection observed.
Gary Maharaj, the President and CEO of Surmodics, commented, “The addition of the Pounce XL Thrombectomy System fulfills our vision of providing a simple, effective platform for removing peripheral arterial blood clots throughout the leg. When minutes matter, physicians appreciate having a readily deployable solution with a proven track record of safe and reliable results. We are excited about the growing clinical adoption of this product and the positive impact it is having on limb ischemia patients who require urgent care.”
The Pounce Thrombectomy Platform consists of the Pounce, Pounce LP, and Pounce XL systems. All are FDA-cleared and fully mechanical, designed for non-surgical clot removal from peripheral arteries. The devices work through a straightforward, “grab-and-go” process, involving three main components: a delivery catheter, a basket wire, and a funnel catheter. The basket wire is guided past the thrombus and deploys two nitinol self-expanding baskets that capture the clot. The clot is then retracted into the nitinol collection funnel, and the system is withdrawn into a 7 Fr guide sheath to remove the clot from the body.
Surmodics, headquartered in Eden Prairie, Minnesota, is dedicated to improving disease detection and treatment through its specialized surface modification and drug-delivery coating technologies. The company also develops and commercializes innovative vascular intervention medical devices, such as the Pounce Thrombectomy Platform, designed to address critical clinical needs. However, it should be noted that the content of Surmodics’ website is not part of this press release or any filings the company makes with the Securities and Exchange Commission.
In conclusion, the launch of the Pounce XL Thrombectomy System further strengthens Surmodics’ position as a key player in the vascular intervention field. The system provides a vital, efficient solution for clinicians treating patients with peripheral arterial thrombosis and embolism, offering benefits such as reduced procedure times, minimized risks, and enhanced patient outcomes.
